Last reviewed · How we verify
NCT04216186
Role of Coenzyme Q in ADHD in Children
Phase 3 trial testing Atomoxetine in ADHD in 40 participants. Currently enrolling.
1 December 2030
Quick facts
| Lead sponsor | Sherief Abd-Elsalam |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 November 2018 |
| Primary completion | 1 December 2030 |
| Estimated completion | 1 December 2030 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Atomoxetine (ATOMOXETINE) — full drug profile →
- Coenzyme Q — full drug profile →
Conditions studied
- ADHD — all drugs for ADHD →
Sponsor
Sherief Abd-Elsalam — full company profile →
Who can join
Adults 2 to 18, any sex, with ADHD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Role of Coenzyme Q in ADHD in Children
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04216186
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Atomoxetine
Trials testing the same drug.
- NCT06573970 — Atomoxetine and Executive Function in PTSD · Phase 4 · not yet recruiting
- NCT07316296 — Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi · Phase 3 · recruiting
- NCT06841666 — Evaluating the Efficacy of Atomoxetine in Reducing Primary Nocturnal Enuresis in Children With ADHD: A Randomized, Place · EARLY_PHASE1 · not yet recruiting
- NCT06542887 — Black Seed Oil in ADHD · Phase 2 · not yet recruiting
- NCT04354103 — Atomoxetine in Patients With Tourette's Syndrome · Phase 2 · terminated
Other recruiting trials for ADHD
Currently open trials in the same condition.
- NCT07314333 — A Trial to Assess How Centanafadine Interacts With Stimulants in the Body · Phase 1 · recruiting
- NCT07262853 — Dual Executive Function Training Package · NA · recruiting
- NCT07291453 — Loving Habits: A Feasibility Study of a Support Program for Building New Parent-child Behavioral Habits · NA · recruiting
- NCT07281092 — Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) · NA · recruiting
- NCT07219810 — Accelerated iTBS Targeting of Working Memory Versus Inhibitory Control in Adolescent ADHD · NA · recruiting
Other Sherief Abd-Elsalam trials
Trials by the same sponsor.
- NCT05291455 — Lacosamide in Neonatal Status Epilepticus · Phase 3 · unknown
- NCT04766177 — Role of Bumetanide in Treatment of Autism · Phase 3 · recruiting
- NCT04499755 — Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics · Phase 3 · recruiting
- NCT04499885 — Potential Role of Gastric Lavage by Paraffin Oil in Acute Aluminum Phosphide Poisoning · NA · recruiting
- NCT04216199 — Role of Point of Care Ultrasound in Endotracheal Tube Placement · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04216186 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sherief Abd-Elsalam
- Last refreshed: 2 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04216186.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing